Participated · Series A · Jul 2026

Flexell Space develops next-generation space solar solutions and announced a $20 million Series A on July 14. The company is identified in the press release as being based in Uiwang, South Korea. Public reporting about the round does not include specifics on product roadmaps, customers, revenues, or other operating metrics. The articles also do not disclose how the company plans to deploy the new capital. No information about prior funding rounds or valuation was provided in the cited coverage.

Participated · Series C · Jul 2026

Founded in 2015, Nexusbe designs ALD equipment and proprietary gas-injector technology that enables nanometer-scale precise thin-film deposition. Its ALD systems are applied across semiconductors, displays, high-efficiency solar cells and secondary-battery electrode and separator coatings, and the company supplies equipment to more than 70 universities and research institutes. Nexusbe established a sales subsidiary in China last year and is expanding local commercial efforts in response to the Chinese solar-cell market. The company reported successive institutional financings since 2021 and has a cumulative funding total of 290억 won following the completed Series C. Management plans to accelerate ALD technology development and scale mass-production deployment, and is preparing for a KOSDAQ IPO with joint lead managers already appointed.

Participated · Series B · Jun 2026

INNOVAID’s Dentlink platform digitizes the end-to-end dental prosthetics workflow, integrating data acquisition, dentist-technician communication, fabrication, quality control, and logistics in a single system. The company says digitization has reduced prosthetic remake rates from around 10% to roughly 1%. Dentlink is live in six countries: the United States, Australia, Canada, New Zealand, Singapore, and the United Kingdom. INNOVAID reports that both clinic count and revenue have grown more than 2.5 times year over year and that its paid customer retention rate in the U.S. is 95%. The company has a strategic partnership with implant manufacturer Straumann to support global expansion. Using Series B proceeds, INNOVAID plans to scale operations in the U.S. and Australia and to build an automated, robot-integrated manufacturing center in Korea.

Participated · Series B · Jun 2026

Promedius develops Osteo Signal, an AI-based screening solution that analyzes routine chest radiographs to assess osteoporosis risk in about three seconds and identify at-risk patient groups without additional tests. Osteo Signal was designated an innovative medical device in 2024 and received approval from the Korean Ministry of Food and Drug Safety in 2025; the company has also secured regulatory approvals in Vietnam and Indonesia and is seeking FDA and CE/MDR clearances by the end of the year. Promedius has built partnerships with global medical device companies such as Siemens Healthineers and secured strategic investors including Daewoong Pharmaceutical and Naver to support commercial rollout. The company aims to commercialize nationally and expand internationally while broadening its platform to address healthy aging conditions like sarcopenia, metabolic and cardiovascular diseases. Its total funding now exceeds 35 billion won following the recent Series B raise of 21.5 billion won.

Participated · Series B · May 2026

Featuring builds influencer marketing solutions and enterprise social data analytics platforms using a proprietary data engine called Featuring AI. The company serves nearly 16,000 clients and reported annual revenue of 9.6 billion won last year, its strongest performance to date. Founded in 2019, Featuring created a Japanese subsidiary last year and is pursuing Korea–Japan cross-border marketing and local network expansion. Management plans to develop vertical AI agents to automate end-to-end influencer marketing operations and to hire key talent to support that growth. Featuring is also considering acquisitions or mergers with local Japanese firms as part of its international expansion strategy.